Market revenue in 2022 | USD 11.3 million |
Market revenue in 2030 | USD 23.6 million |
Growth rate | 9.6% (CAGR from 2022 to 2030) |
Largest segment | Gene panel, ldt & others |
Fastest growing segment | Gene Panel, LDT & Others |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Panel, LDT & Others |
Key market players worldwide | Illumina Inc, Exact Sciences Corp, Foundation Medicine, Guardant Health Inc, Burning Rock Biotech Ltd ADR, Freenome, AnchorDx, GeneCast, Elypta |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to multi cancer early detection market will help companies and investors design strategic landscapes.
Gene panel, ldt & others was the largest segment with a revenue share of 100% in 2022. Horizon Databook has segmented the Mexico multi cancer early detection market based on gene panel, ldt & others covering the revenue growth of each sub-segment from 2018 to 2030.
In Mexico, mortality and incidence of breast cancer have increased in the past few years. Changes in healthcare policies in the country include various programs for access to early diagnosis and treatment against breast cancer. High breast cancer incidence in the country is leading to increase in the usage of various novel early cancer detection techniques.
Breast cancer accounted for 7,931 deaths in 2020, followed by prostate cancer, which caused around 7,457 deaths in the same year. Furthermore, Mexico's MCED market is growing at a high rate due to increasing collaborations between key market players.
This agreement enabled availability of Clear ID Breast Cancer for customers through Milenia Labs and its network of 12 diagnostic centers in the country. In June 2022, a new agreement to enhance oncology care in Mexico extended the long-term partnership between Medica Sur and Mayo Clinic.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico multi cancer early detection market , including forecasts for subscribers. This country databook contains high-level insights into Mexico multi cancer early detection market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account